Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 7/20 | 0.43 |
| ▸ | RIPK3 | Q9Y572 | 2/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26090514 | 0.80 | EPHX2 (0.51) | ALDH1A1EPHX2 | |
| SCHEMBL26087416 | 0.79 | LIPE (0.43) | KDRRIPK1RIPK3BRAFFFAR4 | |
| SCHEMBL27352139 | 0.75 | EPHX2 (0.47) | KDRBRAFALDH1A1POLBFFAR4 | |
| SCHEMBL31417741 | 0.75 | EPHX2 (0.47) | KDRBRAFALDH1A1POLBFFAR4 | |
| SCHEMBL31417546 | 0.74 | KMT2A (0.55) | ALDH1A1 | |
| SCHEMBL31417701 | 0.72 | NPC1 (0.47) | KDRBRAFALDH1A1POLBFFAR4 | |
| SCHEMBL31417602 | 0.72 | FFAR4 (0.37) | KDRRIPK1RIPK3BRAFKDM4E | |
| SCHEMBL29041928 | 0.72 | WDR5 (0.42) | KDRRIPK1RIPK3ALDH1A1POLB | |
| SCHEMBL1984984 | 0.71 | SMN1; SMN2 (0.49) | KDRBRAFALDH1A1POLBFFAR4 | |
| SCHEMBL20707888 | 0.71 | RIPK1 (0.53) | KDRRIPK1RIPK3BRAFFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025016457-A1 | NEW SUBSTITUTED HETEROCYCLIC COMPOUND AS GSPTS/MYC SIGNAL FLUX REGULATOR | 杭州德睿智药科技有限公司 | 2025-01-23 | — | — | WO | disclosed |
| US-20240294495-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-05 | — | — | US | disclosed |
| WO-2023069731-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294495-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | CRBN, GSPT1, GSPT2 | KDR 3592/4885HTR2C 3276/4885RIPK1 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.